Cryptococcus neoformans capsule structure evolution in vitro and during murine infection

Infection and Immunity

Volumn 72, Issue 6, 2004, Pages 3359-3365

  Garcia Hermoso, Dea ^a   Dromer, Françoise ^a   Janbon, Guilhem ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; EPITOPE; FLUCONAZOLE; ITRACONAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIGEN EXPRESSION; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; EVOLUTION; FLOW CYTOMETRY; FUNGAL STRAIN; FUNGUS CULTURE; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; BRAIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; EVOLUTION, MOLECULAR; FLOW CYTOMETRY; GENOTYPE; HUMANS; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; PHENOTYPE; POLYSACCHARIDES; VIRULENCE;

EID: 2542599333     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.6.3359-3365.2004     Document Type: Article

References (34)

1. Bose, I., A. J. Reese, J. J. Ory, G. Janbon, and T. L. Doering. 2003. A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot. Cell 2:655-663.
2. Brandt, M. E., C. Hutwagner, L. A. Klug, W. S. Baughman, D. Rimland, E. A. Graviss, R. J. Hamill, C. Thomas, P. G. Pappas, A. L. Reingold, R. W. Pinner, and the Cryptococcal Disease Active Surveillance Group. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J. Clin. Microbiol. 34:912-917.
3. Buchanan, K. L., and J. W. Murphy. 1998. What makes Cryptococcus neoformans a pathogen? Emerg. Infect. Dis. 4:71-83.
4. Cherniak, R., L. C. Morris, T. Belay, E. D. Spitzer, and A. Casadevall. 1995. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect. Immun. 63:1899-1905.
5. 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5:146-159.
6. Cleare, W., R. Cherniak, and A. Casadevall. 1999. In vitro and in vivo stability of Cryptococcus neoformans glucuronoxylomannan epitope that elicits protective antibodies. Infect. Immun. 67:3096-3107.
7. Currie, B., H. Sanati, A. F. Ibrahim, J. E. Edwards, Jr., A. Casadevall, and M. A. Ghannoum. 1995. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob. Agents Chemother. 39:1934-1937.
8. Dromer, F., J. Salamero, A. Contrepois, C. Carbon, and P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:742-748.
9. Dromer, F., A. Varma, O. Ronin, S. Mathoulin, and B. Dupont. 1994. Molecular typing of Cryptococcus neoformans serotype D clinical isolates. J. Clin. Microbiol. 32:2364-2371.
10. Edman, J. C. 1992. Isolation of telomere-like sequences from Cryptococcus neoformans and their use in high-efficiency transformation. Mol. Cell. Biol. 12:2777-2783.
11. Franzot, S. P., J. Mukherjee, R. Cherniak, L. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89-97.
12. Fries, B., and A. Casadevall. 1998. Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J. Infect. Dis. 178:1761-1766.
13. Fries, B. C., F. Chen, B. P. Currie, and A. Casadevall. 1996. Karyotype instability in Cryptococcus neoformans infection. J. Clin. Microbiol. 34:1531-1534.
14. Fries, B. C., D. L. Goldman, and A. Casadevall. 2002. Phenotypic switching in Cryptococcus neoformans. Microbes Infect. 4:1345-1352.
15. Fries, B. C., C. P. Taborda, E. Serfass, and A. Casadevall. 2001. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J. Clin. Investig. 108:1639-1648.
16. Garcia-Hermoso, D., F. Dromer, S. Mathoulin-Pellissier, and G. Janbon. 2001. Are two Cryptococcus neoformans strains epidemiologically linked? J. Clin. Microbiol. 39:1402-1406.
17. Hull, C. M., and J. Heitman. 2002. Genetics of Cryptococcus neoformans. Annu. Rev. Genet. 36:557-615.
18. Janbon, G., U. Himmelreich, F. Moyrand, L. Improvisi, and F. Dromer. 2001. Cas1p is a membrane protein necessary for the O-acetylation of the cryptococcus neoformans capsular polysaccharide. Mol. Microbiol. 42:453-469.
19. Klepser, M. E., and M. A. Pfaller. 1998. Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994. J. Clin. Microbiol. 36:3653-3656.
20. Kozel, T. R., S. M. Levitz, F. Dromer, M. A. Gates, P. Thorkildson, and G. Janbon. 2003. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O-acetylation or xylosyl side chains. Infect. Immun. 71:2868-2875.
21. Lipovsky, M. M., G. Gekker, S. Hu, L. C. Ehrlich, I. M. Hoepelman, and P. K. Peterson. 1998. Cryptococcal glucuronoxylomannan induces interleukin-8 (IL-8) production by human microglia but inhibits neutrophil migration toward IL-8. J. Infect. Dis. 177:260-263.
22. Lortholary, O., L. Improvisi, M. Nicolas, F. Provost, B. Dupont, and F. Dromer. 1999. Fungemia during cryptococcosis sheds some light on pathophysiology. Med. Mycol. 37:169-174.
23. Lortholary, O., L. Improvisi, N. Rayhane, F. Gray, C. Fitting, J. M. Cavaillon, and F. Dromer. 1999. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect. Immun. 67:6314-6320.
24. Moyrand, F., B. Klaproth, U. Himmelreich, F. Dromer, and G. Janbon. 2002. Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol. Microbiol. 45:837-849.
25. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Pietrella, D., B. L. Fries, P. Lupo, F. Bistoni, A. Casadevall, and A. Vecchiarelli. 2003. Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response. Cell. Microbiol. 5:513-522.
27. Rivera, J., M. Feldmesser, M. Cammer, and A. Casadevall. 1998. Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect. Immun. 66:5027-5030.
28. Salas, S. D., J. E. Bennett, K. J. Kwon-Chung, J. R. Perfect, and P. R. Williamson. 1996. Effect of the laccase gene, CNLAC1, on virulence of Cryptococcus neoformans. J. Exp. Med. 184:377-386.
29. Small, J. M., and T. G. Mitchell. 1989. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A. Infect. Immun. 57:3751-3756.
30. Spitzer, E. D., and S. G. Spitzer. 1992. Use of dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neoformans. J. Clin. Microbiol. 30:1094-1097.
31. Sullivan, D., K. Haynes, G. Moran, D. Shanley, and D. Coleman. 1996. Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients. J. Clin. Microbiol. 34:1739-1744.
32. Summer, E. R., and S. V. Avery. 2002. Phenotypic heterogeneity: differential stress resistance among individual cells of the yeast Saccharomyces cerevisiae. Microbiology 148:345-351.
33. Varma, A., and K. J. Kwon-Chung. 1991. Rapid method to extract DNA from Cryptococcus neoformans. J. Clin. Microbiol. 29:810-812.
34. Yue, C., L. M. Cavallo, J. A. Alspaugh, P. Wang, G. M. Cox, J. R. Perfect, and J. Heitman. 1999. The STE12α homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics 153:1601-1615.